Medical News

RSS

Xcellerex, SK Chemicals sign memorandum of understanding to expand vaccine business in Korea

Xcellerex, Inc. announced today that it has signed a memorandum of understanding with SK Chemicals, Co., Ltd., one of South Korea's largest industrial groups, for an alliance to develop and commercialize SK-developed vaccines with Xcellerex's FlexFactory biomanufacturing platform. The companies expect to define specific terms of the alliance in the coming months.

26 Aug 2010

First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

OXIS INTERNATIONAL, INC. is proud to announce that it has initiated active planning for the First World Congress on Ergothioneine, to be held in Los Angeles, California in July 2011 (the specific date will be announced at a later date).

26 Aug 2010

maxIT Healthcare ranked number 3264 on Inc. 5000 list of fastest growing private companies

maxIT Healthcare, a leading professional consulting services company for healthcare providers, has been recognized by Inc. magazine on its third annual Inc. 5000 list of the nation's fastest growing private companies. With three year sales growth of over 59%, maxIT was ranked number 3264 on the list. This is the second consecutive year that maxIT has made the list.

26 Aug 2010

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.

26 Aug 2010

FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for use of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for active immunization of infants and toddlers for the prevention of invasive meningococcal disease caused by serogroups A, C, Y, and W-135.

26 Aug 2010

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

Medtronic, Inc. today announced it received Health Canada approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a novel radiofrequency ablation technology for the treatment of atrial fibrillation. AF is the most common heart arrhythmia that affects more than 250,000 Canadians and seven million people worldwide.

26 Aug 2010

NeoPharm second-quarter net loss decreases to $0.8 million

NeoPharm, Inc., a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative therapeutic applications of drugs for various forms of cancer and other diseases, today announced its second quarter 2010 financial results.

26 Aug 2010

DMAHS awards four-year Medicaid utilization review contract to Permedion

HMS announced today that the State of New Jersey Department of Human Services Division of Medical Assistance and Health Services has awarded a contract to Permedion, Inc., HMS's wholly owned subsidiary, to conduct utilization reviews, medical necessity audits, and Diagnosis Related Group validations of inpatient hospital medical services provided and billed for Medicaid beneficiaries.

26 Aug 2010

DePuy Orthopaedics announces voluntary recall of ASR XL Acetabular and Hip Resurfacing systems

DePuy Orthopaedics, Inc., announced it is voluntarily recalling the ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System used in hip replacement surgery due to the number of patients who required a second hip replacement procedure, called a revision surgery.

26 Aug 2010

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

Cardioxyl Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutic agents for the treatment of cardiovascular disease, today announced that it has initiated a dose-defining Phase IIa trial of its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure.

26 Aug 2010

FORTUNE ranks China-Biotics 62nd on 2010 'Fastest-Growing Companies' list

China-Biotics, Inc., a leading developer, manufacturer and distributor of probiotics products in China, today announced that the Company is ranked 62nd on FORTUNE's 2010 "Fastest-Growing Companies" list.

26 Aug 2010

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Alexza Pharmaceuticals, Inc. announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by delivering nicotine via inhalation, mimicking the nicotine effects of smoking without the harmful side effects associated with cigarettes.

26 Aug 2010

Aon Consulting survey finds increase in monthly COBRA contributions for terminated employees

As the national unemployment rate continues to hover around 10 percent, health care costs for those jobless Americans have seen a year-over-year increase, according to Aon Consulting, the global benefits and human capital consulting business of Aon Corporation.

26 Aug 2010

Restat announces signing of PEBA as latest Align cost-plus pricing model client

Restat, the nation's largest independent pharmacy benefits manager has announced the signing of the Public Employee Benefits Alliance as its latest Align cost-plus pricing model client. PEBA, an organization formed by several Texas government employers, cooperatively purchases employee benefits -- including health care benefits -- on behalf of the local government entities.

26 Aug 2010

Health care in New Orleans five years after Hurricane Katrina

Availability to news media of physicians, community leaders and others involved in post-Katrina health care.

26 Aug 2010

CDC study examines cost of medical care, productivity losses associated with motor vehicle injuries

In a one-year period, the cost of medical care and productivity losses associated with injuries from motor vehicle crashes exceeded $99 billion - with the cost of direct medical care accounting for $17 billion, according to a study by the Centers for Disease Control and Prevention. The total annual cost amounts to nearly $500 for each licensed driver in the United States, said the study in the journal Traffic Injury Prevention.

26 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

26 Aug 2010

YFALS Campaign to appear in Milwaukee, Atlanta and Seattle

The Young Faces of ALS Campaign raises awareness of ALS and those diagnosed with the progressive neurodegenerative disease at a young age. Starting today, the campaign will make stops at Major League Baseball ballparks in Milwaukee, Atlanta and Seattle.

26 Aug 2010

Momenta Pharmaceuticals provides update on generic Lovenox litigation

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that on August 25, 2010, the United States District Court for the District of Columbia denied sanofi-aventis U.S. LLC's request for a preliminary injunction directing the FDA to suspend and withdraw its approval of the Abbreviated New Drug Application (ANDA) filed by the Company's collaboration partner, Sandoz, for enoxaparin sodium injection USP, a generic version of Lovenox®. The decision is subject to appeal.

26 Aug 2010

Pathogens can delay entry into cells to ensure their survival, say researchers

Pathogens make themselves feel at home in the human body, invading cells and living off the plentiful amenities on offer. However, researchers at the Max Planck Institute for Infection Biology, Berlin, together with colleagues at Harvard University, reveal an opposite strategy used to ensure infection success. Pathogens can actually delay their entry into cells to ensure their survival.

26 Aug 2010

Medical News

Xcellerex, SK Chemicals sign memorandum of understanding to expand vaccine business in Korea

First World Congress on Ergothioneine to be held in Los Angeles, California in July 2011

maxIT Healthcare ranked number 3264 on Inc. 5000 list of fastest growing private companies

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

FDA accepts Sanofi Pasteur's Menactra vaccine sBLA for active immunization of infants and toddlers

Medtronic Ablation Frontiers Cardiac Ablation System receives Health Canada approval

NeoPharm second-quarter net loss decreases to $0.8 million

DMAHS awards four-year Medicaid utilization review contract to Permedion

DePuy Orthopaedics announces voluntary recall of ASR XL Acetabular and Hip Resurfacing systems

Dose-defining Phase IIa trial of CXL-1020 initiated for treating patients with ADHF

FORTUNE ranks China-Biotics 62nd on 2010 'Fastest-Growing Companies' list

Alexza Pharmaceuticals licenses Staccato nicotine technology to Cypress Bioscience

Aon Consulting survey finds increase in monthly COBRA contributions for terminated employees

Restat announces signing of PEBA as latest Align cost-plus pricing model client

Health care in New Orleans five years after Hurricane Katrina

CDC study examines cost of medical care, productivity losses associated with motor vehicle injuries

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

YFALS Campaign to appear in Milwaukee, Atlanta and Seattle

Momenta Pharmaceuticals provides update on generic Lovenox litigation

Pathogens can delay entry into cells to ensure their survival, say researchers

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News